1. Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting

2. First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer (EBC) Presented By Eric Winer at 2014 ASCO Annual Meeting

3. N9831/B-31 Disease-Free Survival Presented By Eric Winer at 2014 ASCO Annual Meeting

4. Pathologic Response in Neo-ALTTO Presented By Eric Winer at 2014 ASCO Annual Meeting

5. CALGB 40601 (TH vs TL vs THL) Presented By Eric Winer at 2014 ASCO Annual Meeting

6. Adjuvant Lapatinib (ALTTO) Schema Presented By Eric Winer at 2014 ASCO Annual Meeting

7. Disease Free Survival (DFS) Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting

8. Disease Free Survival By Hormone Receptor Status Presented By Eric Winer at 2014 ASCO Annual Meeting

9. Slide 9 Presented By Eric Winer at 2014 ASCO Annual Meeting

10. Overall Survival (OS) Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting

11. Main Differences In AEs By Treatment Arm Presented By Eric Winer at 2014 ASCO Annual Meeting

12. Thoughts About ALTTO Presented By Eric Winer at 2014 ASCO Annual Meeting

13. Further Implications for Research and Practice Presented By Eric Winer at 2014 ASCO Annual Meeting

14. Why Improvement in Pathologic Complete Response May Not Lead to Change in DFS Presented By Eric Winer at 2014 ASCO Annual Meeting

15. Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal Women with Hormone Receptor Positive Early Breast Cancer: Joint Analysis of IBCSG TEXT and SOFT Presented By Eric Winer at 2014 ASCO Annual Meeting

16. Study Schemas (Total N=4690) Presented By Eric Winer at 2014 ASCO Annual Meeting

17. Improved DFS with Exemestane + OFS vs Tamoxifen + OFS Presented By Eric Winer at 2014 ASCO Annual Meeting

18. Sites of First Failure Presented By Eric Winer at 2014 ASCO Annual Meeting

19. Overall Survival at 5 Years Presented By Eric Winer at 2014 ASCO Annual Meeting

20. Women Who Did Not Receive Chemotherapy Presented By Eric Winer at 2014 ASCO Annual Meeting

21. Selected Adverse Events Presented By Eric Winer at 2014 ASCO Annual Meeting

22. Adverse Events and QOL Presented By Eric Winer at 2014 ASCO Annual Meeting

23. Slide 23 Presented By Eric Winer at 2014 ASCO Annual Meeting

24. Does Ovarian Suppression Add To Tamoxifen In Premenopasual Women? Findings FromThe LHRH Meta-Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting

25. Slide 25 Presented By Eric Winer at 2014 ASCO Annual Meeting

26. Primary End Point: Disease-Free Survival No Significant Difference Between TAM and ANA Presented By Eric Winer at 2014 ASCO Annual Meeting

27. Is OS + AI The New Standard of Care? Presented By Eric Winer at 2014 ASCO Annual Meeting

28. What To Consider When You Go Home (1) Presented By Eric Winer at 2014 ASCO Annual Meeting

29. What To Consider When You Go Home (2) Presented By Eric Winer at 2014 ASCO Annual Meeting

30. Thank you Presented By Eric Winer at 2014 ASCO Annual Meeting